{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T13:01:56Z","timestamp":1785589316130,"version":"3.56.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008903","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["NHRI- EX112-11133NI"],"award-info":[{"award-number":["NHRI- EX112-11133NI"]}],"id":[{"id":"10.13039\/100008903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.schres.2023.06.006","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:55:16Z","timestamp":1688000116000},"page":"34-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A brief history of clozapine use in Taiwan"],"prefix":"10.1016","volume":"268","author":[{"given":"Shih-Ku","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien-Yuan","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2023.06.006_bb0005","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1192\/bjp.194.5.468a","article-title":"Clozapine and risk of pneumonia","volume":"194","author":"Abdelmawla","year":"2009","journal-title":"Br. J. Psychiatry"},{"issue":"Suppl","key":"10.1016\/j.schres.2023.06.006_bb0010","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1007\/BF00442556","article-title":"Clozapine--pharmacokinetic investigations and biochemical effects in man","volume":"99","author":"Ackenheil","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2023.06.006_bb0015","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.schres.2020.05.013","article-title":"Antipsychotic medications and the progression of upper respiratory infection to pneumonia in patients with schizophrenia","volume":"222","author":"Chang","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.06.006_bb0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/BF00187266","article-title":"Time-response curves of homovanillic acid in caudate and pre-frontal cortex following acute neuroleptic administration","volume":"93","author":"Chang","year":"1987","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2023.06.006_bb0025","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/BF00172955","article-title":"Dose-response curves of homovanillic acid in pre-frontal cortex and caudate following antipsychotic drugs: relation to clinical potencies","volume":"95","author":"Chang","year":"1988","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2023.06.006_bb0030","first-page":"599","article-title":"Clozapine dosages and plasma drug concentrations","volume":"96","author":"Chang","year":"1997","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.schres.2023.06.006_bb0035","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0378-4347(93)80212-M","article-title":"Determination of clozapine and desmethylclozapine in human plasma by high-performance liquid chromatography with ultraviolet detection","volume":"613","author":"Chung","year":"1993","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.schres.2023.06.006_bb0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0957154X07070335","article-title":"The history of clozapine and its emergence in the US market: a review and analysis","volume":"18","author":"Crilly","year":"2007","journal-title":"Hist. Psychiatry"},{"key":"10.1016\/j.schres.2023.06.006_bb0045","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-004-2017-1","article-title":"The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine\u2019s actions?","volume":"178","author":"Davies","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2023.06.006_bb0050","doi-asserted-by":"crossref","first-page":"411","DOI":"10.24869\/psyd.2022.411","article-title":"Reflections on the complex history of the concept of clozapine-induced inflammation during titration","volume":"34","author":"De Leon","year":"2022","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.schres.2023.06.006_bb0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/IJPSYM.IJPSYM_379_19","article-title":"Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical overview","volume":"42","author":"De Leon","year":"2020","journal-title":"Indian J. Psychol. Med."},{"key":"10.1016\/j.schres.2023.06.006_bb0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/a-1625-6388","article-title":"An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels","volume":"55","author":"De Leon","year":"2022","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"10.1016\/j.schres.2023.06.006_bb0065","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.mehy.2012.10.014","article-title":"The dopamine D4\/D2 receptor antagonist affinity ratio as a predictor of anti-aggression medication efficacy","volume":"80","author":"El-Mallakh","year":"2013","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.schres.2023.06.006_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113201","article-title":"Targeting muscarinic receptors to treat schizophrenia","volume":"405","author":"Foster","year":"2021","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.schres.2023.06.006_bb0075","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0920-9964(99)00002-X","article-title":"Effects of clozapine and haloperidol on 5-HT6 receptor mRNA levels in rat brain","volume":"38","author":"Frederick","year":"1999","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.06.006_bb0080","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/biom9060234","article-title":"Clozapine normalizes a glutamatergic transmission abnormality induced by an impaired NMDA receptor in the thalamocortical pathway via the activation of a group III metabotropic glutamate receptor","volume":"9","author":"Fukuyama","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.schres.2023.06.006_bb0085","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1017\/S1461145708009085","article-title":"Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation","volume":"12","author":"Gray","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2023.06.006_bb0090","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-3-642-25758-2_7","article-title":"The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions","volume":"213","author":"Gross","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.schres.2023.06.006_bb0095","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/00004714-199812000-00010","article-title":"Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia","volume":"18","author":"Guitton","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.06.006_bb0100","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0924-977X(03)00042-7","article-title":"Toxic rise of clozapine plasma concentrations in relation to inflammation","volume":"13","author":"Haack","year":"2003","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2023.06.006_bb0105","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004714-199408000-00011","article-title":"Elevated levels of clozapine in serum after addition of fluvoxamine","volume":"14","author":"Hiemke","year":"1994","journal-title":"Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.06.006_bb0110","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1007\/s00198-005-1928-y","article-title":"Down-regulation of N-methyl D-aspartate receptor in rat-modeled disuse osteopenia","volume":"16","author":"Ho","year":"2005","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.schres.2023.06.006_bb0115","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.7150\/ijms.63246","article-title":"Risk of pneumonia is associated with antipsychotic drug use among older patients with Parkinson\u2019s disease: a case-control study","volume":"18","author":"Huang","year":"2021","journal-title":"Int. J. Med. Sci."},{"issue":"77","key":"10.1016\/j.schres.2023.06.006_bb0120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4088\/JCP.14m09301","article-title":"Antipsychotic reexposure and recurrent pneumonia in schizophrenia: a nested case-control study","volume":"2016","author":"Hung","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.06.006_bb0125","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00007691-199408000-00006","article-title":"Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service","volume":"16","author":"Jerling","year":"1994","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.schres.2023.06.006_bb0130","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/biomedicines10020398","article-title":"Drug design targeting the muscarinic receptors and the implications in central nervous system disorders","volume":"10","author":"Johnson","year":"2022","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.schres.2023.06.006_bb0135","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0009-9236(98)90174-6","article-title":"Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping","volume":"64","author":"Kashuba","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.schres.2023.06.006_bb0140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/bs.apha.2017.09.009","article-title":"Unique effects of clozapine: a pharmacological perspective","volume":"82","author":"Khokhar","year":"2018","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.schres.2023.06.006_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.pscychresns.2020.111128","article-title":"The relationship between plasma levels of clozapine and N-desmethyclozapine as well as M1 receptor polymorphism with cognitive functioning and associated cortical activity in schizophrenia","volume":"303","author":"Kir","year":"2020","journal-title":"Psychiatry Res. Neuroimaging"},{"key":"10.1016\/j.schres.2023.06.006_bb0150","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/schbul\/sbr202","article-title":"Second-generation antipsychotic medications and risk of pneumonia in schizophrenia","volume":"39","author":"Kuo","year":"2013","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2023.06.006_bb0155","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12911-019-0792-1","article-title":"Predicting hospital-acquired pneumonia among schizophrenic patients: a machine learning approach","volume":"19","author":"Kuo","year":"2019","journal-title":"BMC Med. Inform. Decis. Mak."},{"key":"10.1016\/j.schres.2023.06.006_bb0160","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s40263-021-00847-4","article-title":"Absolute and dose-adjusted serum concentrations of clozapine in patients switching vs. maintaining treatment: an observational study of 1979 patients","volume":"35","author":"Kylles\u00f8","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2023.06.006_bb0165","first-page":"297","article-title":"Increased use of antibiotics in clozapine-treated patients","volume":"18","author":"Landry","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.06.006_bb0170","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4088\/JCP.v60n0108","article-title":"Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics","volume":"60","author":"Lane","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.06.006_bb0175","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bdi.12272","article-title":"Clozapine for treatment-resistant bipolar disorder: a systematic review","volume":"17","author":"Li","year":"2015","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.schres.2023.06.006_bb0180","article-title":"Cardiac complications associated with short-term mortality in schizophrenia patients hospitalized for pneumonia: a nationwide case-control study","volume":"8","author":"Liao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.schres.2023.06.006_bb0185","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/JCP.0000000000000692","article-title":"Clotiapine monotherapy in a patient with clozapine-resistant schizophrenia","volume":"37","author":"Lin","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"issue":"23","key":"10.1016\/j.schres.2023.06.006_bb0190","first-page":"00171","article-title":"Sodium benzoate: A novel multi-target pharmaceutical approach to rescue clozapine-resistant schizophrenia","volume":"S0920-9964","author":"Lin","year":"2023","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.06.006_bb0195","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1038\/s41598-019-40691-7","article-title":"Long-term use of clozapine is protective for bone density in patients with schizophrenia","volume":"9","author":"Lin","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.schres.2023.06.006_bb0200","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/j.1552-4604.1994.tb02000.x","article-title":"Disposition of clozapine and desmethylclozapine in schizophrenic patients","volume":"34","author":"Lin","year":"1994","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.06.006_bb0205","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.ftd.0000211801.66569.80","article-title":"Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive\/compulsive symptoms","volume":"28","author":"Lin","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.schres.2023.06.006_bb0210","doi-asserted-by":"crossref","first-page":"594","DOI":"10.4088\/JCP.v61n0809","article-title":"Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients","volume":"61","author":"Lu","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.06.006_bb0215","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4088\/JCP.v65n0607","article-title":"Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances","volume":"65","author":"Lu","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.06.006_bb0220","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.schres.2017.06.030","article-title":"Effects of adjunctive fluvoxamine on metabolic parameters and psychopathology in clozapine-treated patients with schizophrenia: a 12-week, randomized, double-blind, placebo-controlled study","volume":"193","author":"Lu","year":"2018","journal-title":"Schizophr. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2023.06.006_bb0225","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/sj.npp.1395370","article-title":"The role of serotonin in antipsychotic drug action","volume":"21","author":"Meltzer","year":"1999","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.schres.2023.06.006_bb0230","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0014-2999(99)00341-6","article-title":"Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors","volume":"376","author":"Michal","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.schres.2023.06.006_bb0235","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41380-020-0709-5","article-title":"Binding of clozapine to the GABAB receptor: clinical and structural insights","volume":"25","author":"Nair","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2023.06.006_bb0240","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2023.06.006_bb0245","article-title":"Current limitations and candidate potential of 5-HT7 receptor antagonism in psychiatric pharmacotherapy","volume":"12","author":"Okubo","year":"2021","journal-title":"Front. Psych."},{"key":"10.1016\/j.schres.2023.06.006_bb0250","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0893-133X(98)00048-7","article-title":"Mixed agonist\u2013antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in chinese hamster ovary cells","volume":"20","author":"Olianas","year":"1999","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.schres.2023.06.006_bb0255","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S2215-0366(23)00002-0","article-title":"Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data","volume":"10","author":"Pardi\u00f1as","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2023.06.006_bb0260","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S8756-3282(98)00061-1","article-title":"Expression of an N-methyl-D-aspartate-type receptor by human and rat osteoblasts and osteoclasts suggests a novel glutamate signaling pathway in bone","volume":"22","author":"Patton","year":"1998","journal-title":"Bone"},{"key":"10.1016\/j.schres.2023.06.006_bb0265","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/ACI.0000000000000592","article-title":"Clozapine-associated secondary antibody deficiency","volume":"19","author":"Ponsford","year":"2019","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"10.1016\/j.schres.2023.06.006_bb0270","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1139\/jpn.0312","article-title":"Interactions between the cytochrome P450 system and the second-generation antipsychotics","volume":"28","author":"Prior","year":"2003","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.schres.2023.06.006_bb0275","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1192\/bjb.2019.50","article-title":"Changes in smoking status, mental state and plasma clozapine concentration: retrospective cohort evaluation","volume":"43","author":"Qurashi","year":"2019","journal-title":"BJPsych Bulletin"},{"issue":"4","key":"10.1016\/j.schres.2023.06.006_bb0280","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.schres.2023.06.006_bb0285","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/157015912799362724","article-title":"Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review","volume":"10","author":"Schirmbeck","year":"2012","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.schres.2023.06.006_bb0290","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/17512433.2021.1877135","article-title":"An update on the complex relationship between clozapine and pneumonia","volume":"14","author":"Schoretsanitis","year":"2021","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2023.06.006_bb0295","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.lfs.2008.05.014","article-title":"Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area","volume":"83","author":"Schwieler","year":"2008","journal-title":"Life Sci."},{"key":"10.1016\/j.schres.2023.06.006_bb0300","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/toxsci\/kfab154","article-title":"Clozapine induces an acute proinflammatory response that is attenuated by inhibition of inflammasome signaling: implications for idiosyncratic drug-induced agranulocytosis","volume":"186","author":"Sernoskie","year":"2022","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.schres.2023.06.006_bb0305","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1055\/s-2007-979221","article-title":"Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial","volume":"32","author":"Szegedi","year":"1999","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2023.06.006_bb0310","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S2215-0366(22)00044-X","article-title":"Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland","volume":"95","author":"Tiihonen","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2023.06.006_bb0315","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bdi.12261","article-title":"Clozapine use reduced psychiatric hospitalization and emergency room visits in patients with bipolar disorder independent of improved treatment regularity in a three-year follow-up period","volume":"17","author":"Wu","year":"2015","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.schres.2023.06.006_bb0320","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/JCP.0000000000001052","article-title":"Estimating the risk of pneumonia in patients with schizophrenia newly receiving clozapine: a nationwide cohort study","volume":"39","author":"Wu","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.06.006_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2019.02.056","article-title":"Clozapine prescription pattern in patients with schizophrenia in Asia: the REAP survey (2016)","volume":"287","author":"Xu","year":"2020","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2023.06.006_bb0330","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.4088\/JCP.12m07938","article-title":"Antipsychotic drugs, mood stabilizers, and risk of pneumonia in bipolar disorder: a nationwide case-control study","volume":"74","author":"Yang","year":"2013","journal-title":"J. Clin. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423002244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423002244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:37:24Z","timestamp":1777581444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996423002244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":66,"alternative-id":["S0920996423002244"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2023.06.006","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A brief history of clozapine use in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2023.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}